Fentanyl in the US heroin supply: A rapidly changing risk environment

International Journal of Drug Policy

Volumn 46, Issue , 2017, Pages 107-111

  Ciccarone, Daniel ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; FENTANYL; ILLICIT DRUG;

CAUSE OF DEATH; DRUG OVERDOSE; DRUG POTENCY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TRAFFIC; EDITORIAL; HEROIN DEPENDENCE; HUMAN; INFORMATION DISSEMINATION; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; RISK REDUCTION; STANDARDIZATION; UNITED STATES; DRUG CONTAMINATION; PREVENTION AND CONTROL; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION;

DRUG CONTAMINATION; DRUG OVERDOSE; FENTANYL; HEROIN; HUMANS; RISK FACTORS; UNITED STATES;

EID: 85025141170     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2017.06.010     Document Type: Editorial

References (53)

1. Baum, R.J., Letter to Congress: Response to questions concerning fentanyl. 2017, Office of National Drug Control Policy, Washington DC.
2. Beletsky, L., Davis, C.S., Today's fentanyl crisis: Prohibition's Iron law, revisited. International Journal of Drug Policy 46 (2017), 156–159, 10.1016/j.drugpo.2017.05.050.
3. Brunt, T.M., Nagy, C., Bücheli, A., Martins, D., Ugarte, M., Beduwe, C., et al. Drug testing in Europe: Monitoring results of the Trans European Drug Information (TEDI) project. Drug Testing and Analysis 9:2 (2017), 188–198.
4. Canadian Community Epidemiology Network on Drug Use, CCENDU, Deaths involving fentanyl in Canada 2009–2014. CCENDU bulletin, 2015, Canadian Centre on Substance Abuse, Canada.
5. Carroll, J.J., Marshall, B.D.L., Rich, J.D., Green, T.C., Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study. International Journal of Drug Policy 46 (2017), 136–145, 10.1016/j.drugpo.2017.05.023.
6. Caudevilla, F., Ventura, M., Fornís, I., Barratt, M.J., Vidal, C., Quintana, P.l, et al. Results of an international drug testing service for cryptomarket users. International Journal of Drug Policy 35 (2016), 38–41.
7. Center for Behavioral Health Statistics and Quality, CBHSQ, Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health. 2015, U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration.
8. Centers for Disease Control and Prevention, CDC, Drug overdose death data. 2016 Last Modified December 16, 2016.
9. Ciccarone, D., The political economy of heroin: Regional markets, practices and consequences. International Journal of Drug Policy 16:5 (2005), 289–290.
10. Ciccarone, D., Heroin in brown, black and white: Structural factors and medical consequences in the US heroin market. International Journal of Drug Policy 20:3 (2009), 277–282, 10.1016/j.drugpo.2008.08.003.
11. Ciccarone, D., Ondocsin, J., Mars, S.G., Heroin uncertainties: Exploring users’ perceptions of fentanyl-adulterated and -substituted ‘heroin’. International Journal of Drug Policy 46 (2017), 146–155, 10.1016/j.drugpo.2017.06.004.
12. Ciccarone, D., Unick, G.J., Kraus, A., Impact of South American heroin on the US heroin market 1993–2004. International Journal of Drug Policy 20:5 (2009), 392–401, 10.1016/j.drugpo.2008.12.001.
13. Ciccarone, D., Unick, G.J., Cohen, J.K., Mars, S.G., Rosenblum, D., Nationwide increase in hospitalizations for heroin-related soft tissue infections: Associations with structural market conditions. Drug and Alcohol Dependence 163 (2016), 126–133.
14. Compton, W.M., Jones, C.M., Baldwin, G.T., Relationship between nonmedical prescription-opioid use and heroin use. New England Journal of Medicine 374:2 (2016), 154–163, 10.1056/NEJMra1508490.
15. Courtwright, D.T., Dark Paradise: A History of Opiate Addiction in America Cambridge. 2001, Harvard University Press, MA.
16. US Drug Enforcement Administration, DEA, National heroin threat assessment summary—Updated. DEA Intelligence Report, 2016, Department of Justice, Washington, DC.
17. Drug Enforcement Administration Diversion Control Division, DEA, National forensic laboratory information system: Year 2015 annual report. Washington, DC: Drug Enforcement Administration, Springfield, VA, 2016.
18. Drug Enforcement Administration, DEA, The heroin signature program and heroin domestic monitor reports 2014. DEA intelligence report. Washington, DC: Department of Justice., Washington DC, 2016.
19. Fairbairn, N., Coffin, P.O., Walley, A.Y., Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. International Journal of Drug Policy 46 (2017), 172–179, 10.1016/j.drugpo.2017.06.005.
20. Firestone, M., Goldman, B., Fischer, B., Fentanyl use among street drug users in Toronto, Canada: Behavioural dynamics and public health implications. International Journal of Drug Policy 20:1 (2009), 90–92.
21. Frank, R.G., Pollack, H.A., Addressing the fentanyl threat to public health. New England Journal of Medicine 376:7 (2017), 605–607.
22. Gilbert, M.K., Dasgupta, N., Silicon to syringe: Cryptomarkets and disruptive innovation in opioid supply chains. International Journal of Drug Policy 46 (2017), 160–167, 10.1016/j.drugpo.2017.05.052.
23. Gladden, R.M., Martinez, P., Seth, P., Fentanyl law enforcement submissions and increases in synthetic opioid–involved overdose deaths—27 states, 2013–2014. MMWR Morbidity and Mortality Weekly Report 65:33 (2016), 837–843.
24. Green, T.C., Gilbert, M., Counterfeit medications and fentanyl. JAMA Internal Medicine 176:10 (2016), 1555–1557.
25. Greenwald, M.K., Behavioral economic analysis of drug preference using multiple choice procedure data. Drug and Alcohol Dependence 93:1 (2008), 103–110.
26. Harm Reduction International, UK, The Global State of Harm Reduction 2016. 2017, Harm Reduction International, London, UK.
27. Harris, M., Forseth, K., Rhodes, T., “It's Russian roulette”: Adulteration, adverse effects and drug use transitions during the 2010/2011 United Kingdom heroin shortage. International Journal of Drug Policy 26:1 (2015), 51–58.
28. Hondebrink, L., Nugteren-van Lonkhuyzen, J.J., Van Der Gouwe, D., Brunt, T.M., Monitoring new psychoactive substances (NPS) in The Netherlands: Data from the drug market and the Poisons Information Centre. Drug and Alcohol Dependence 147 (2015), 109–115.
29. Katz, J., Drug deaths in America are rising faster than ever. New York Times, 2017 5th June 2017.
30. Katz, J., You draw it: Just how bad is the drug overdose epidemic?. New York Times, 2017 14 April 2017.
31. Kolodny, A., Courtwright, D.T., Hwang, C.S., Kreiner, P., Eadie, J.L., Clark, T.W., et al. The prescription opioid and heroin crisis: A public health approach to an epidemic of addiction. Annual Review of Public Health 36 (2015), 559–574.
32. Larney, S., Peacock, A., Mathers, B.M., Hickman, M., Degenhardt, L., A systematic review of injecting-related injury and disease among people who inject drugs. Drug & Alcohol Dependence 171 (2017), 39–49.
33. Latimer, J., Ling, S., Flaherty, I., Jauncey, M., Salmon, A.M., Risk of fentanyl overdose among clients of the Sydney Medically Supervised Injecting Centre. International Journal of Drug Policy 37 (2016), 111–114.
34. Lucyk, S.N., Nelson, L.S., Toxicosurveillance in the US Opioid Epidemic. International Journal of Drug Policy 46 (2017), 168–171, 10.1016/j.drugpo.2017.05.057.
35. Madras, B.K., The surge of opioid use, addiction, and overdoses: Responsibility and response of the US health care system. Jama Psychiatry 74:5 (2017), 441–442.
36. Mars, S., Bourgois, P., Karandinos, G., Montero, F., Ciccarone, D., “Every ‘never’ I ever said came true”: Transition from opioid to heroin injecting. International Journal of Drug Policy 25:2 (2014), 257–266, 10.1016/j.drugpo.2013.10.004.
37. Marshall, B.D.L., Krieger, M.S., Yedinak, J.L., Ogera, P., Alexander-Scott, N.E., Rich, J.D., et al. Epidemiology of fentanyl-involved drug overdose deaths: A geospatial retrospective study in Rhode Island, USA. International Journal of Drug Policy 46 (2017), 130–135, 10.1016/j.drugpo.2017.05.029.
38. Marshall, B.D.L., Milloy, M.J., Wood, E., Montaner, J.S.G., Kerr, T., Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: A retrospective population-based study. The Lancet 377:9775 (2011), 1429–1437.
39. McCoy, A.W., The Politics of Heroin: CIA Complicity in the Global Drug Trade, Afghanistan, Southeast Asia, Central America, Columbia. revised edition, 2003, Chicago Review Press, Chicago.
40. Monnat, S.M., Deaths of despair and support for Trump in the 2016 Presidential Election. 2016, Pennsylvania State University, Department of Agricultural Economics Research Brief.
41. Paoli, L., Greenfield, V.A., Reuter, P., The World Heroin Market: Can Supply be Cut?. 2009, Oxford University Press, New York.
42. Potier, C., Laprévote, V., Dubois-Arber, F., Cottencin, O., Rolland, B., Supervised injection services: what has been demonstrated? A systematic literature review. Drug and Alcohol Dependence 145 (2014), 48–68.
43. Quinones, S., Dreamland: The True Tale of America's Opiate Epidemic. 2015, Bloomsbury Press, New York, NY and London, UK.
44. Roxburgh, A., Burns, L., Drummer, O.H., Pilgrim, J., Farrell, M., Degenhardt, L., Trends in fentanyl prescriptions and fentanyl-related mortality in Australia. Drug and Alcohol Review 32:3 (2013), 269–275.
45. Slavova, S., Costich, J.F., Bunn, T.L., Luu, H., Singleton, M., Hargrove, S.L., et al. Heroin and fentanyl overdoses in Kentucky: Epidemiology and surveillance. International Journal of Drug Policy 46 (2017), 120–129, 10.1016/j.drugpo.2017.05.051.
46. Somerville, N.J., O'Donnell, J., Gladden, R.M., Zibbell, J.E., Green, T.C., Younkin, S., et al. Characteristics of fentanyl overdose—Massachusetts, 2014–2016. MMWR Morbidity and Mortality Weekly Report 66 (2017), 382–386, 10.15585/mmwr.mm6614a2.
47. Suzuki, J., El-Haddad, S., A review: Fentanyl and non-pharmaceutical fentanyls. Drug and Alcohol Dependence 171 (2017), 107–116.
48. Unick, G.J., Ciccarone, D., US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations. International Journal of Drug Policy 46 (2017), 112–119, 10.1016/j.drugpo.2017.06.003.
49. Unick, G.J., Rosenblum, D., Mars, S., Ciccarone, D., Intertwined epidemics: National demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993–2009. PLoS One, 8(2), 2013, e54496, 10.1371/journal.pone.0054496.
50. United Nations Office of Drug Control, UNODC, World Drug Report., 2016, United Nations, New York.
51. Warner, M., Trinidad, J.P., Bastian, B.A., Miniño, A.M., Hedegaard, H., Drugs most frequently involved in drug overdose deaths: United States, 2010–2014. National vital statistics reports: From Centers for Disease Control and Prevention. Hyattsville, MD: National Center for Health Statistics, National Vital Statistics System 65:10 (2016), 1–15.
52. Xu, J.Q., Murphy, S.L., Kochanek, K.D., Arias, E., Mortality in the United States, 2015. NCHS data brief, 2016, National Center for Health Statistics, Hyattsville, MD.
53. Zibbell, J.E., Iqbal, K., Patel, R.C., Suryaprasad, A., Sanders, K.J., Moore-Moravian, L., et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years-Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morbidity and Mortality Weekly Report 64:17 (2015), 453–458.